GlassScriptPhysician profile
Victoria E Plauche
NPI 1992183305
$5,804.74
in general payments reported to CMS, 2019-2025
52 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $991 · 2023: $1,125 · 2024: $1,311 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,978.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $589.30 | 2021-2025 | Keytruda, Welireg, Reblozyl |
| Novartis Pharmaceuticals Corporation | $524.53 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $409.87 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Janssen Biotech, INC. | $315.92 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Incyte Corporation | $302.83 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $299.88 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $297.75 | 2021-2025 | Opdualag, Opdivo, Krazati |
| Daiichi Sankyo INC. | $230.25 | 2021-2025 | Enhertu, Datroway |
| Celgene Corporation | $200.26 | 2022-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $156.62 | 2021-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Genzyme Corporation | $138.85 | 2021-2025 | |
| Beone Medicines USA, INC. | $137.63 | 2025 | Brukinsa |
| Eisai INC. | $132.85 | 2021-2025 | |
| Abbvie INC. | $131.36 | 2024-2025 | |
| Caris Mpi, INC. | $121.26 | 2025 | Mi Cancer Seek |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $115.34 | 2022-2025 | Ultomiris |
| Beigene USA, INC. | $109.45 | 2021-2024 | Brukinsa |
| Astellas Pharma US INC | $107.71 | 2021-2025 | Xospata, Vyloy, Padcev |
| Gilead Sciences, INC. | $94.12 | 2022-2023 | Trodelvy |
| Jazz Pharmaceuticals INC. | $93.57 | 2022-2025 | |
| Sobi, INC | $90.31 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $86.16 | 2022-2025 | |
| Genentech USA, INC. | $83.64 | 2021-2023 | Tecentriq |
| Glaxosmithkline, LLC. | $76.36 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Exelixis INC. | $64.97 | 2021-2025 | Cabometyx |
| Lilly USA, LLC | $64.64 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $57.71 | 2023-2025 | Fotivda |
| Emd Serono, INC. | $57.36 | 2024-2025 | |
| Seagen INC. | $55.84 | 2023 | Tukysa, Adcetris |
| Rigel Pharmaceuticals, INC. | $51.54 | 2023-2024 | Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $51.40 | 2022-2025 | Onivyde, Somatuline Depot |
| Geron Corporation | $47.62 | 2024-2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $47.60 | 2022-2025 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $47.36 | 2021-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $43.52 | 2021-2025 | Xpovio |
| Servier Pharmaceuticals LLC | $34.93 | 2024-2025 | |
| Array Biopharma INC | $34.79 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $33.86 | 2023 | Kyprolis, Lumakras |
| Puma Biotechnology, INC. | $30.92 | 2021-2024 | |
| Taiho Oncology, INC. | $30.01 | 2022-2023 | |
| Blueprint Medicines Corporation | $28.52 | 2022-2024 | Ayvakit |
| Legend Biotech USA INC. | $20.94 | 2025 | Carvykti |
| Pharmaessentia USA Corporation | $19.89 | 2025 | Besremi |
| Genmab U.S., INC. | $18.85 | 2024 | Tivdak |
| Sun Pharmaceutical Industries INC. | $16.88 | 2024 | |
| Adc Therapeutics America, INC. | $16.83 | 2024 | |
| Acrotech Biopharma INC. | $15.34 | 2022 | |
| Epizyme, INC. | $15.22 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.10 | 2024 | Vivimusta |
| Pharmacyclics LLC, An Abbvie Company | $12.74 | 2021 | |
| Cti Biopharma Corp. | $12.56 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Plauche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.